Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) EBT Margin (2016 - 2025)

Historic EBT Margin for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to 3.06%.

  • Lifecore Biomedical, Inc. \De\'s EBT Margin rose 158000.0% to 3.06% in Q2 2025 from the same period last year, while for May 2025 it was 30.01%, marking a year-over-year decrease of 374300.0%. This contributed to the annual value of 30.01% for FY2025, which is 374300.0% down from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical, Inc. \De\'s EBT Margin is 3.06%, which was up 158000.0% from 42.04% recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s EBT Margin peaked at 47.02% during Q4 2023, and registered a low of 118.05% during Q2 2023.
  • Its 5-year average for EBT Margin is 24.26%, with a median of 20.71% in 2022.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s EBT Margin crashed by -1044600bps in 2023 and then soared by 992000bps in 2024.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s EBT Margin stood at 4.97% in 2021, then crashed by -947bps to 42.06% in 2022, then skyrocketed by 212bps to 47.02% in 2023, then plummeted by -143bps to 20.05% in 2024, then surged by 85bps to 3.06% in 2025.
  • Its last three reported values are 3.06% in Q2 2025, 42.04% for Q1 2025, and 20.05% during Q4 2024.